Harvard Bioscience Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Harvard Bioscience şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

1.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: HBIO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: HBIO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Harvard Bioscience Piyasaya Karşı Temettü Getirisi

HBIO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HBIO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Life Sciences)	0.5%
Analist tahmini (HBIO) (3 yıla kadar)	n/a

Önemli Temettü: HBIO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, HBIO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: HBIO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: HBIO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Harvard Bioscience Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024

Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual Meeting

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought US$75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought US$83k worth of stock

President recently bought US$128k worth of stock

Forecast breakeven date pushed back to 2023

Price target decreased to US$8.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought US$111k worth of stock

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

President recently bought US$147k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Full year 2021 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

President recently sold US$386k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Price target increased to US$9.67

Harvard Bioscience, Inc. Files A Motion to Vacate the Suffolk Superior Court’S Order Allowing Plaintiff’S Motion for Sanctions

Independent Director has left the company

President notifies of intention to sell stock